Reactivation of CDKL5 Using Epigenetic Editors

Abstract

Researchers at the University of California, Davis have developed a targeted gene editing system that reactivates the silenced CDKL5 gene by precise epigenetic modulation to treat CDKL5 deficiency disorder (CDD).

Full Description

This technology provides compositions and methods utilizing a split, catalytically inactive CRISPR-Cas9 (dCas9) fused to epigenetic effectors, including TET1 dioxygenase and transcriptional activators, to selectively demethylate and activate the CDKL5 gene on the inactive X chromosome. The system employs multiplexed guide RNAs and compact promoters optimized for efficient delivery and specific targeting within one kilobase of the CDKL5 transcriptional start site. It offers a modular platform for reversible epigenetic reprogramming to increase CDKL5 expression, with applications in treating disorders caused by CDKL5 gene silencing such as CDKL5 deficiency disorder.

Applications

• Therapeutic treatment for CDKL5 deficiency disorder and related neurodevelopmental diseases. 
• Gene therapy platforms targeting epigenetic dysregulation in X-linked genetic disorders. 
• Research tools for epigenetic editing and study of X-chromosome inactivation dynamics. 
• Personalized medicine approaches for allelic reactivation in female carriers of X-linked diseases. 
• Development of viral vector-based delivery systems for in vivo gene modulation. 
• Potential extension to other diseases driven by epigenetic gene silencing or DNA methylation abnormalities.

Features/Benefits

• Precision targeting of CDKL5 promoter using CRISPR-dCas9 fused to TET1 catalytic domain for site-specific DNA demethylation. 
• Multiplexed guide RNA array allows simultaneous multi-site targeting to enhance gene activation. 
• Compact genetic elements tailored for efficient packaging in viral vectors like AAV. 
• Split dCas9 design overcomes size constraints, enabling delivery of large fusion proteins. 
• Potential for reversible and allele-specific reactivation of silenced X-linked genes. 
• Versatile delivery options including lentiviral, adenoviral, and adeno-associated viral vectors. 
• Applicable to cultured cells, primary cells, and in vivo treatment of mammalian subjects. 
• Overcomes lack of targeted epigenetic editing methods specific for X-linked genes. 
• Enables reactivation of silenced CDKL5 gene to address CDKL5 deficiency disorder. 
• Reduces off-target and global side effects seen in non-specific DNA demethylating treatments. 
• Addresses mosaic expression issues due to X-chromosome inactivation in females. 
• Supports gene activation despite epigenetic barriers like promoter hypermethylation. 
• Facilitates study and modulation of X-chromosome inactivation escape mechanisms.

Patent Status

Patent Pending